“The Supreme Court’s ruling to reject dubious anti-abortion efforts to restrict access to mifepristone, a vital medication approved by the Food and Drug Administration (FDA) is a welcome relief. For over two decades, mifepristone has served more than 5 million women and birthing people with access to safe and effective abortion and miscarriage care. New York City is a safe harbor for anyone seeking abortion and reproductive care, and the Council will continue to protect and expand this access. While this decision is a victory for reproductive rights, it was based on standing and not substance and we must remain vigilant against further attempts to erode our reproductive healthcare rights and the ability to make the best choice for ourselves.”